Tag: Sulfonamide AMPA potentiator

  • PEPA

    Sulfonamide AMPA potentiator

    A potent benzothiazide AMPA potentiator used principally as a research probe for AMPA receptor pharmacology.

    Abstract

    PEPA (4-[2-(phenylsulfonylamino)ethylthio]-2,6-difluoro-phenoxyacetamide; CAS 158235-23-7) is a potent sulfonamide-class AMPA receptor positive allosteric modulator developed as a research tool compound. The compound shows substantially greater AMPA potentiation per molecule than the marketed and Phase 2 ampakines, but with poor pharmacokinetic properties (low oral bioavailability, short plasma half-life) that limit clinical translation. PEPA is used principally as a research probe for AMPA receptor pharmacology in vitro and ex vivo. The compound has not been advanced to human clinical trials and has no significant research-chemical-grade availability outside academic research supply chains.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Org-26576

    Sulfonamide AMPA potentiator

    An Organon/Merck ampakine that reached Phase 2 in major depressive disorder.

    Abstract

    Org-26576 is a sulfonamide-class AMPA receptor positive allosteric modulator developed by Organon (subsequently Schering-Plough, Merck) for cognitive enhancement in major depressive disorder and other indications. The compound advanced through Phase 2 trials with results consistent with the ampakine class profile (modest cognitive endpoint improvements, no adverse signal). The development program was discontinued under Merck. Pharmacokinetics: plasma half-life approximately 5 hours; oral bioavailability adequate. The compound is rarely available in research-chemical-grade markets.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.